US OptionsDetailed Quotes
NMRA241220P10000
- 0.05
- 0.000.00%
15min DelayClose Dec 20 16:00 ET
0.00High0.00Low
0.00Open0.05Pre Close0 Volume5.45K Open Interest10.00Strike Price0.00Turnover4921.86%IV-405.08%PremiumDec 20, 2024Expiry Date8.03Intrinsic Value100Multiplier-13DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.1246Delta0.2622Gamma39.40Leverage Ratio-101.4856Theta0.0000Rho-4.91Eff Leverage0.0000Vega
Neumora Therapeutics Stock Discussion
Sign in to post a comment
NOTE!
1. NFA (Not Financial Advice!)
2. Do not open position without chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 CH (cash on hand); AH (after hours): RTH (regular trading hours)
7. Remember, some stocks may get pumped WITHOUT any catalyst
8. It’s 2025, those newbies need to read and educ...
1. NFA (Not Financial Advice!)
2. Do not open position without chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 CH (cash on hand); AH (after hours): RTH (regular trading hours)
7. Remember, some stocks may get pumped WITHOUT any catalyst
8. It’s 2025, those newbies need to read and educ...
47
26
11
$Neumora Therapeutics (NMRA.US)$ Pre-Market Updates
Neumora Therapeutics, Inc. (NASDAQ: NMRA) announced that the Phase 3 KOASTAL-1 study of navacaprant for major depressive disorder did not show a statistically significant improvement in the primary endpoint of change in MADRS score at Week 6 or the key secondary endpoint of SHAPS score. The KOASTAL-2, KOASTAL-3, and KOASTAL-LT studies are ongoing.
Neumora Therapeutics, Inc. (NASDAQ: NMRA) announced that the Phase 3 KOASTAL-1 study of navacaprant for major depressive disorder did not show a statistically significant improvement in the primary endpoint of change in MADRS score at Week 6 or the key secondary endpoint of SHAPS score. The KOASTAL-2, KOASTAL-3, and KOASTAL-LT studies are ongoing.
1
6
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Neumora Therapeutics (NMRA.US)$ Nmra Study Did Not Demonstrate Statistically Significant Improvement On Primary Endpoint Of Reduction In Depressive Symptoms As Measured By MADRS Total Score Compared To Placebo
1
$Neumora Therapeutics (NMRA.US)$ Buy Rating Maintained for Neumora Therapeutics Due to Promising
MDD Trial Results and Strong
Financial Position
MDD Trial Results and Strong
Financial Position
9
2
Let's work hard together.
$Neumora Therapeutics (NMRA.US)$ The number of shares either being flipped or just plain being bought at 1.95/1.959 is crazy! Hehehe! But this sure looks like another overreaction and a opportunity! Im sure there was probably a large amount of buyers sitting on the sidelines waiting for a lower price to buy? Well if so, they definitely got their shot now! Hehehe! NFA Just thinking outloud ![]()
14
if drops a bit more 
price still going down.
battle of the titans
No comment yet
151713027 : What is NFA
Jaguar8 OP 151713027 : Not financial advice
151713027 Jaguar8 OP : Thanks
Christy 8866 : Hi Jaguar, I have a really stupid question for you, maybe you can explain a bit , sorry, I don’t have much knowledge about the financial background. I have a stock is dropping a lot , but i heard it might be reverse split in next few weeks, what’s reverse split? Is it good or bad ? Should I wait or just sell it to stop further losses. Thank you
Mangkawat Christy 8866 : which one stock?
View more comments...